Literature DB >> 10800950

p-ethynylphenylalanine: a potent inhibitor of tryptophan hydroxylase.

A H Stokes1, Y Xu, J A Daunais, H Tamir, M D Gershon, P Butkerait, B Kayser, J Altman, W Beck, K E Vrana.   

Abstract

Tryptophan hydroxylase (TPH) is the initial and rate-limiting enzyme in serotonin biosynthesis. The enzyme activity is dependent on molecular oxygen, a tetrahydropterin cosubstrate, and ferrous iron. The present study demonstrates that TPH is inhibited by a novel compound, p-ethynylphenylalanine (pEPA), produced by the Heck reaction of trimethylsilylacetylene with N-tertbutyloxycarbonyl-4-iodo-L-phenylalanine methyl ester. pEPA is a more potent and specific inhibitor of TPH than p-chlorophenylalanine (pCPA). In the present study, pEPA was demonstrated to inhibit competitively and reversibly TPH in vitro (Ki = 32.6 +/- 6.2 microM vs. tryptophan). pEPA displayed little inhibitory activity toward tyrosine hydroxylase (EC 1.14.16.2), the initial and rate-limiting enzyme for catecholamine biosynthesis, and no inhibition of phenylalanine hydroxylase or tyrosinase. In addition, pEPA was a poor ligand for the serotonin transporter and several serotonin receptors. Administration of pEPA (30 mg/kg) to rats produced a 95 +/- 5% decrease in TPH activity in brain homogenates and a concomitant decrease in serotonin and 5-hydroxyindole-3-acetic acid levels (85%) at 24 h after injection. In contrast, pCPA produced a similar effect (87 +/- 5% decrease in TPH activity) only at 10 times the concentration (300 mg/kg). These results suggest that pEPA is a selective, reversible, and potent inhibitor of TPH both in vitro and in vivo. The potential for pEPA to inhibit selectively and reversibly the biosynthesis of serotonin may contribute to the characterization of the role of serotonin in behavioral and physiological activities.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10800950     DOI: 10.1046/j.1471-4159.2000.0742067.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  De novo microdeletion of Xp11.3 exclusively encompassing the monoamine oxidase A and B genes in a male infant with episodic hypotonia: a genomics approach to personalized medicine.

Authors:  Ryan E O'Leary; Jean C Shih; Keith Hyland; Nancy Kramer; Y Jane Tavyev Asher; John M Graham
Journal:  Eur J Med Genet       Date:  2012-02-03       Impact factor: 2.708

2.  A genetic approach to access serotonin neurons for in vivo and in vitro studies.

Authors:  Michael M Scott; Christi J Wylie; Jessica K Lerch; Roxanne Murphy; Katherine Lobur; Stefan Herlitze; Weihong Jiang; Ron A Conlon; Ben W Strowbridge; Evan S Deneris
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-26       Impact factor: 11.205

3.  Phenylalanine Monitoring via Aptamer-Field-Effect Transistor Sensors.

Authors:  Kevin M Cheung; Kyung-Ae Yang; Nako Nakatsuka; Chuanzhen Zhao; Mao Ye; Michael E Jung; Hongyan Yang; Paul S Weiss; Milan N Stojanović; Anne M Andrews
Journal:  ACS Sens       Date:  2019-11-01       Impact factor: 7.711

4.  Short- and long-term effects of p-ethynylphenylalanine on brain serotonin levels.

Authors:  Luc Zimmer; André Luxen; Fabrice Giacomelli; Jean-François Pujol
Journal:  Neurochem Res       Date:  2002-04       Impact factor: 3.996

5.  Mouse plasmacytoma-expressed transcript 1 knock out induced 5-HT disruption results in a lack of cognitive deficits and an anxiety phenotype complicated by hypoactivity and defensiveness.

Authors:  T L Schaefer; C V Vorhees; M T Williams
Journal:  Neuroscience       Date:  2009-09-25       Impact factor: 3.590

6.  Cryo-EM Structure and Activator Screening of Human Tryptophan Hydroxylase 2.

Authors:  Kongfu Zhu; Chao Liu; Yuanzhu Gao; Jianping Lu; Daping Wang; Huawei Zhang
Journal:  Front Pharmacol       Date:  2022-08-15       Impact factor: 5.988

7.  The antimalarial drug quinine interferes with serotonin biosynthesis and action.

Authors:  Farida Islahudin; Sarah M Tindall; Ian R Mellor; Karen Swift; Hans E M Christensen; Kevin C F Fone; Richard J Pleass; Kang-Nee Ting; Simon V Avery
Journal:  Sci Rep       Date:  2014-01-09       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.